Rani, Celltrion expand partnership for development of adalimumab biosimilar
Under a new license and supply agreement, Celltrion will supply adalimumab biosimilar drug substance CT-P17 that is required for RT-105. Rani has an exclusive license to use the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.